US · PHARMACEUTICAL PREPARATIONS
BIO Essence Corp. BIOE
6 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$1.9M
▲ 485.8% vs FY2024
EPS · FY25
—
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
47.2%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 1.9M
Revenue, FY2025 · full 6-year series below
Revenue
Net income
47 cents of every revenue dollar became profit this year.
Per share
—
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin47.4%
Net margin47.2%
Return on assets254.8%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+14.6% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+45.1%
+14.6%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.04B
Shares outstanding, FY2025
Change, 5 years+15.1%
Change, 10 years—
The share count grew 15% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 422,474.00
total assets, end of FY2025
Total assetsUSD 422,474.00
EquityUSD -2.1M
Gross debtUSD 57,482.00
Current ratio0.17×
Equity funds -491% of total assets.
History
6 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
·
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
·
−0.03
−0.03
−0.02
−0.02
−0.02
Dividend / sh $
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
ROE %
·
·
·
·
·
·
Shares out B
0.04
0.04
0.04
0.03
0.03
0.03
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
23 of 23
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed